This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
August 2, 2012, 04:30 pm ET
Ron Ellis – CEO, President
Mike Sherman – CFO
(Matt McCavaney) – Robert W Baird
Adnan Butt – RBC Capital Markets
Simos Simeonidis – Cowen and Company
Welcome to Endocyte's conference call to discuss the company's second quarter 2012 financial results and business update. At this time, all participants are in a listen-only mode.
Speaking today will be Ron Ellis, President and CEO; and Mike Sherman, Chief Financial Officer. Following comments by Ron and Mike, we will open the lines for questions.
Please be advised that today's call is being recorded and webcast. During the conference call, the company may make predictive statements concerning future events or development such as their expectations for the EU regulatory filing, regulatory approvals, timing of clinical trial execution, clinical trial results and financial outlook.
Actual results may differ materially from those indicated by forward-looking statements due to a variety of risks and uncertainties. Please refer to Endocyte's filings with the Securities and Exchange Commission for a discussion of these risks and uncertainties.
Now let me turn the call over to Ron Ellis.
Thanks, everyone, for being on the call this afternoon. We'll have a brief just update on some milestones and then I'll have Mike Sherman go through the financials. As, first off, we announced this morning that we've secured additional supply of DOXIL from Janssen.
We had supply as we announced earlier to cover us for the clinical trial and the enrollment we had and we felt comfortable with that. This provides some more insurance cushion to handle more patients as we bring more sites online and give us just more cushion in terms of the DOXIL supply.